@article{Kodad_2023, place={Toronto, Canada}, title={Management of limited stage Hodgkin lymphoma}, volume={2}, url={https://canadianhematologytoday.com/article/view/2-1-3-kodad}, DOI={10.58931/cht.2023.2123}, abstractNote={<p>Hodgkin lymphoma (HL) is a lymphoid neoplasm characterized by malignant lymphocytes, known as Reed-Sternberg cells, on a background of non-neoplastic inflammatory cells. Lugano staging determines the stage of Hodgkin lymphoma, which, in turn, determines the treatment and prognosis. Limited-stage disease is defined as Stage I and Stage II, which is diagnosed in more than 50% of patients. Pre-treatment risk stratification, PET-adapted therapy, and combined modality treatment have significantly improved cure rates, making limited-stage HL one of the most curable malignancies. In this article, we discuss the current approach to managing limited-stage HL.</p>}, number={1}, journal={Canadian Hematology Today}, author={Kodad, Shruthi}, year={2023}, month={Mar.}, pages={16–20} }